A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma | MicrobiomeTrials← Back to trialsNCT06942442
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-10-22Est. Completion: 2030-10-01
Enrollment target: 47 participants Locations- University of Southern California - Norris Cancer Center, Los Angeles, California, United States
- Northwestern University, Chicago, Illinois, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Royal Marsden, London, United Kingdom
Other microbiome trials you might be interested in
Head and Neck Squamous Cell CarcinomaHPV Positive Oropharyngeal Squamous Cell CarcinomaNew Diagnosis TumorLocally Advanced
This is a phase 2, pilot, randomized, open-label 3-arm study to assess the safety, tolerability, and efficacy of CUE-101…
New Haven, United StatesEst. completion Feb 2031
Metastatic Uveal Melanoma
This study is a multicenter, open label phase I/ II trial to assess the safety and clinical efficacy of tebentafusp-tebn…
Philadelphia, United StatesEst. completion Oct 2030